LCTX Earnings

Quarterly EPS
$-0.02
Q3 2024
$-0.01
Q4 2024
$-0.02
Q1 2025
$-0.13
Q2 2025
$-0.13
Q3 2025
$0.00
Q4 2025
$-0.02
Q1 2026
$0.01
Q2 2026
Latest Revenue1.1M
Latest Net Income1.5M
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q2 2026$0.011.1M1.5M-61.3%+107.7%
Q1 2026-$0.021.7M-4789000+14.8%+0.0%
Q4 2025$0.006.6M892.0K+130.4%+100.0%
Q3 2025-$0.133.7M-29752000-2.6%-550.0%
Q2 2025-$0.132.8M-30364000+96.4%-333.3%
Q1 2025-$0.021.5M-4143000+4.0%+50.0%
Q4 2024-$0.012.9M-3250000+37.4%+66.7%
Q3 2024-$0.023.8M-3001000+203.3%+50.0%
Q2 2024-$0.031.4M-5773000——
Q1 2024-$0.041.4M-6558000——
Q4 2023-$0.032.1M-4714000——
Q3 2023-$0.041.2M-7158000——
Lineage Cell Therapeutics (LCTX) — Earnings